BioRestorative Therapies, Inc.
BRTX
$0.18
-$0.01-6.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -10.30% | 1.70% | 247.62% | 161.54% | 175.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.30% | 1.70% | 247.62% | 161.54% | 175.03% |
| Cost of Revenue | -15.00% | 3.24% | 409.23% | -- | -- |
| Gross Profit | -9.95% | 1.59% | 241.35% | 140.87% | 155.83% |
| SG&A Expenses | 8.95% | -10.15% | -24.17% | -36.08% | -44.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.88% | 19.52% | 4.72% | -7.71% | -22.19% |
| Operating Income | -35.41% | -20.07% | -1.45% | 9.58% | 24.08% |
| Income Before Tax | -58.61% | -31.34% | -183.12% | -121.20% | 13.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.61% | -31.34% | -183.12% | -121.20% | 13.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.61% | -31.34% | -183.12% | -121.20% | 13.81% |
| EBIT | -35.41% | -20.07% | -1.45% | 9.58% | 24.08% |
| EBITDA | -35.82% | -20.16% | -1.25% | 9.91% | 24.50% |
| EPS Basic | -37.78% | -1.54% | -360.63% | -17.60% | 59.07% |
| Normalized Basic EPS | -68.18% | 12.95% | -284.67% | -0.74% | 66.48% |
| EPS Diluted | -37.78% | -1.54% | -355.38% | -17.21% | 59.13% |
| Normalized Diluted EPS | -68.18% | 12.95% | -284.67% | -0.74% | 66.48% |
| Average Basic Shares Outstanding | 15.85% | 24.41% | 38.64% | 65.15% | 84.08% |
| Average Diluted Shares Outstanding | 15.85% | 24.41% | 38.64% | 65.15% | 84.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |